Skip to main content
Drug misuse and dependency

Guidance and regulation

72 results sorted by Most viewed
  • Briefing for drug and alcohol commissioners and providers about men who have sex with men (MSM) who use drugs before or during sexual activity (chemsex).

  • This professional resource outlines how providers and commissioners can prevent deaths from drug abuse.

  • Guide for commissioners on how to carry out an SROI evaluation for substance misuse prevention, treatment and recovery interventions.

  • Information for drug services to help them prevent, identify, treat and manage wounds in people who inject drugs.

  • Advice for prescribers on the risk of misuse of pregabalin and gabapentin, and suggestions for a balanced and rational use of these medicines.

  • Information on developing local joint protocols between drug and alcohol services, and children and family services.

  • PHE NW Education, Training and Employment (ETE) forum advise on considerations for ETE support for clients in drug and alcohol treatment.

  • Resource for commissioners, providers and clinicians to identify the essential functions of addiction specialist doctors in recovery oriented treatment.

  • The Home Secretary has accepted the ACMD’s recommendation to reclassify methylamphetamine to a Class A Drug.  Methylamphetamine (commonly referred…

  • This essential guide for drug and treatment professionals provides the most up to date scientific evidence on the health harms arising from drug misuse.

  • Provides classifications, conventions used and other background information on the drug misuse releases.

  • Quality governance guidance for local commissioners of alcohol and drug services.

  • Guidance to help health professionals prevent child exploitation and protect vulnerable children that have been manipulated and coerced into crime.

  • Guidance for workers involved in managing TB and substance misuse and guidance for those affected and their families.

  • Guidance on commissioning and providing injectable opioid treatment for people with opioid dependence who have not responded to oral treatment.

  • This guidance is to help researchers comply with the Psychoactive Substances Act, which comes into effect on 26 May 2016.

  • Explains regulations that widen the availability of naloxone, a drug used as an antidote for heroin (or other opiate) overdoses.

  • Briefings on the health harms associated with drug use based on presentations and discussions at the meeting of the national intelligence network.

  • Outlining what part 2 of the independent review will cover.

  • ACMD recommendations regarding gamma-butyrolactone (GBL) and 1,4-BD. Date: Wed Aug 06 16:27:07 BST 2008 Full Document ACMD report on gamma…